Motif’s Clinical Advisory Board continues to strengthen. Today’s appointments will help in the development and commercialisation of Motif’s flagship antibiotic, iclaprim. Motif is now on the cusp of completing its clinical programme for iclaprim, with a read-out expected in H2-2017 for its final Phase 3 trial, REVIVE-2. The group recently announced positive results in its REVIVE-1 Phase 3 trial on iclaprim.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Northland Capital Partners Morning Report
- Published:
10 May 2017 -
Author:
Vadim Alexandre -
Pages:
8
Motif’s Clinical Advisory Board continues to strengthen. Today’s appointments will help in the development and commercialisation of Motif’s flagship antibiotic, iclaprim. Motif is now on the cusp of completing its clinical programme for iclaprim, with a read-out expected in H2-2017 for its final Phase 3 trial, REVIVE-2. The group recently announced positive results in its REVIVE-1 Phase 3 trial on iclaprim.